Literature DB >> 29123250

Parkinson disease: What goes around comes around: cognitive impairment as prodromal parkinsonism?

Yaroslau Compta1, Maria J Martí2.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 29123250     DOI: 10.1038/nrneurol.2017.159

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 2.  MDS clinical diagnostic criteria for Parkinson's disease.

Authors:  Ronald B Postuma; Daniela Berg; Matthew Stern; Werner Poewe; C Warren Olanow; Wolfgang Oertel; José Obeso; Kenneth Marek; Irene Litvan; Anthony E Lang; Glenda Halliday; Christopher G Goetz; Thomas Gasser; Bruno Dubois; Piu Chan; Bastiaan R Bloem; Charles H Adler; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

Review 3.  MDS research criteria for prodromal Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Charles H Adler; Bastiaan R Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

Review 4.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

Review 5.  Challenges in detecting disease modification in Parkinson's disease clinical trials.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  Parkinsonism Relat Disord       Date:  2016-07-31       Impact factor: 4.891

6.  Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].

Authors:  Alex Iranzo; Francisco Lomeña; Heike Stockner; Francesc Valldeoriola; Isabel Vilaseca; Manel Salamero; Jose Luis Molinuevo; Monica Serradell; Joan Duch; Javier Pavía; Judith Gallego; Klaus Seppi; Birgit Högl; Eduard Tolosa; Werner Poewe; Joan Santamaria
Journal:  Lancet Neurol       Date:  2010-09-16       Impact factor: 44.182

Review 7.  The Parkinson Progression Marker Initiative (PPMI).

Authors: 
Journal:  Prog Neurobiol       Date:  2011-09-14       Impact factor: 10.885

8.  Association Between Poor Cognitive Functioning and Risk of Incident Parkinsonism: The Rotterdam Study.

Authors:  Sirwan K L Darweesh; Frank J Wolters; Ronald B Postuma; Bruno H Stricker; Albert Hofman; Peter J Koudstaal; M Kamran Ikram; M Arfan Ikram
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

9.  Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

Authors:  Yaroslau Compta; Laura Parkkinen; Sean S O'Sullivan; Jana Vandrovcova; Janice L Holton; Catherine Collins; Tammaryn Lashley; Constantinos Kallis; David R Williams; Rohan de Silva; Andrew J Lees; Tamas Revesz
Journal:  Brain       Date:  2011-05       Impact factor: 13.501

10.  PREDICT-PD: identifying risk of Parkinson's disease in the community: methods and baseline results.

Authors:  Alastair J Noyce; Jonathan P Bestwick; Laura Silveira-Moriyama; Christopher H Hawkes; Charles H Knowles; John Hardy; Gavin Giovannoni; Saiji Nageshwaran; Curtis Osborne; Andrew J Lees; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-07-04       Impact factor: 10.154

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.